[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604344":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":25,"responsibleParty":44,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Epiliquid Holding, Inc","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"CRC Cases",null,"Individuals with histologically confirmed colorectal adenocarcinoma",{"label":13,"type":10,"description":14,"interventionNames":10},"Controls","Individuals with negative colonoscopy results and no history of colorectal cancer",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Dr. Victoria Bocanegra, MD, PhD.","CONTACT","+5492616603254","victoria.bocanegra@epiliquid.com",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Dr. Emanuel Campoy, PhD.","+5492615997899","emanuel.campoy@epiliquid.com",[26],{"facility":27,"status":28,"city":29,"state":10,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Epiliquid","RECRUITING","Mendoza","5500","Argentina","AR",{"type":34,"coordinates":35},"Point",[36,37],-68.84582,-32.88946,{"lat":37,"lon":36},[40],{"name":41,"role":18,"phone":42,"phoneExt":10,"email":43},"Alejandro Ledesma, M.Sc","+549 1140681732","alejandro.ledesma@epiliquid.com",{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100604344","colorectal-analysis-for-signature-cancer-assessment-using-delta-hld-100604344",false,"NCT07148297","Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD","Proof-of-concept Case-control Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CASCADE)","CASCADE","Inclusion Criteria:\n\n* Candidate for colonoscopy or colorectal surgery\n* Willing and able to provide informed consent\n* Able to provide blood and\u002For tissue sample before treatment or resection\n\nExclusion Criteria:\n\n* Prior history of colorectal cancer\n* Inflammatory bowel disease\n* Known hereditary cancer syndromes (e.g., Lynch, FAP)\n* Other active malignancies\n* Recent chemotherapy or immunosuppressive treatment","ALL","45 Years","75 Years",{"count":58,"type":59},600,"ESTIMATED","OBSERVATIONAL","CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methylation biomarkers for different cancer types. In this study, colorectal cancer-specific biomarkers will be evaluated in blood and tissue samples using delta-HLD technology, which enables sensitive and multiplexed detection through PCR. Study results will support the validation of Epiliquid's integrated platform as a minimally invasive and accessible diagnostic solution for colorectal cancer.",[63],"Colo-rectal Cancer",[65,66,67,68,69,70,71],"Colorectal cancer","Epigenetics","Liquid Biopsy","cfDNA","Biomarker","Methylation","PCR","2025-08-22",{"date":74,"type":75},"2025-08-29","ACTUAL",{"date":77,"type":75},"2021-06-30",{"date":79,"type":59},"2026-12",{"name":5,"class":6},1]